Dizhe Pharmaceutical (688192.SH): Shuoze® monotherapy achieves positive top-line results in international multicenter Phase III clinical trial for first-line treatment of EGFR exon20ins non-small cell lung cancer

iFintech News APP, Dexcel Pharma (688192.SH) announced that their self-developed product, ZOVOFY® (ZEGFROVY®, generic name: Surufatinib tablets), has achieved the primary endpoint and positive topline results in the international multicenter Phase III clinical trial “Wu-Kong 28” (WU-KONG28) for first-line treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins). This is the world’s first and only oral targeted drug to achieve positive results in a global multicenter randomized Phase III clinical trial for first-line treatment of EGFR exon20ins NSCLC.